Federal Register / Vol. 60, No. 96 / Thursday, May 18, 1995 / Proposed Rules 26709

cancer chemotherapy drugs to be used,

based on in vitro analysis of their effects

on cancer cells taken from an

individual.

(E) Topical application of oxygen.

(F) Immunotherapy for malignant

disease.

(G) Prolotherapy, joint sclerotherapy,

and ligamentous injections with

sclerosing agents.

(H) Transcervical block silicone plug.

(I) Whole body hyperthermia in the

treatment of cancer.

(J) Portable nocturnal hypoglycemia

detectors.

(K) Testosterone pellet implants in the

treatment of females.

(L) Estradiol pellet implants.

(M) Epikeratophakia for treatment of

aphakia and myopia.

(N) Bladder stimulators.

(O) Ligament replacement with

absorbable copolymer carbon fiber

scaffold.

(P) Intraoperative radiation therapy.

(Q) Gastric bubble or balloon.

(R) Single and dual photon

absorptiometry for the detection and

monitoring of osteoporosis.

(S) Dorsal root entry zone (DREZ)

thermocoagulation or microcoagulation

neurosurgical procedure.

(T) Brain electrical activity mapping

(BEAM).

(U) Topographic brain mapping

(TBM) procedure.

(V) Ambulatory blood pressure

monitoring.

(W) Bilateral carotid body resection to

relieve pulmonary symptoms.

(X) Intracavitary administration of

cisplatin for malignant disease.

(Y) Cervicography.

(Z) Ambulatory home monitoring—

uterine contractions.

(AA) Sperm evaluation, hamster

penetration test.

(BB) Transfer factor (TF).

(CC) Continuous ambulatory

esophageal pH monitoring (CAEpHM) is

considered investigational for patients

under age 12 for all indications, and for

patients over age 12 for sleep apnea.

(DD) Adrenal-to-brain transplantation

for Parkinson’s disease.

(EE) Videofluoroscopy evaluation in

speech pathology.

(FF) Herniography.

(GG) Applied kinesiology.

(HH) Hair analysis to identify mineral

deficiencies from the chemical

composition of the hair. Hair analysis

testing may be reimbursed when

necessary to determine lead poisoning.

(II) Iridology (links flaws in eye

coloration with diseases elsewhere in

the body).

(JJ) Small intestinal bypass

(jejunoileal bypass) for treatment of

morbid obesity.

(KK) Biliopancreatic bypass.

(LL) Gastric wrapping/gastric

banding.

(MM) Calcium EAP/calcium orotate

and selenium (also known as Nieper

therapy)—Involves inpatient care and

use of calcium compounds and other

non-FDA approved drugs and special

diets. Used for cancer, heart disease,

diabetes, and multiple sclerosis.

(NN) Percutaneous balloon

valvuloplasty for mitral and tricuspid

valve stenosis.

(OO) Amniocentesis performed for

ISO immunization to the ABO blood

antigens.

(PP) Balloon dilatation of the prostate.

(QQ) Helium in radiosurgery.

(RR) Palladium 103Pd) seed

brachytherapy.

(SS) Electrostimulation of salivary

production in the treatment of

xerostomia secondary to Sjorgren’s

syndrome.

(TT) Interaoperative monitoring of

sensory evoked potentials (SEP). To

include visually evoked potentials,

brainstem auditory evoked response,

somatosensory evoked potentials during

spinal and orthopedic surgery, and

sensory evoked potentials monitoring of

the sciatic nerve during total hip

replacement. Recording SEPs in

unconscious head injured patients to

assess the status of the somatosensory

system. The use of SEPs to define

conceptional or gestational age in

preterm infants.

(UU) Autolymphocyte therapy (ALT)

(immunotherapy used for treating

metastatic kidney cancer patients).

(VV) Radioimmunoguided surgery in

the detection of cancer.

(WW) HLA–DNA typing.

(XX) Gait analysis (also known as a

walk study or electrodynogram).

(YY) Cryosurgery for liver metastases.

(ZZ) Use of cerebellar stimulators/

pacemakers for the treatment of

neurologic disorders.

(AAA) Signal-averaged ECG.

(BBB) Intraventricular administration

of narcotics.

(CCC) Peri-urethral Teflon injections

to manage urinary incontinence.

(DDD) Extraoperative

electrocorticography for stimulation and

recording in order to determine

electrical thresholds of neurons as an

indicator of seizure focus.

(EEE) Quantitative computed

tomography (QCT) for the detection and

monitoring of osteoporosis.

(FFF) Percutaneous transluminal

angioplasty in the treatment of

obstructive lesions of the carotid,

vertebral and cerebral arteries.

(GGG) Endoscopic third

ventriculostomy.

(HHH) Holding therapy—Involves

holding the patient in an attempt to

achieve interpersonal contact, and to

improve the patient’s ability to

concentrate on learning tasks.

(III) In utero fetal surgery.

(JJJ) Light therapy for seasonal

depression (also known as seasonal

affective disorder (SAD)).

(KKK) Transurethral laser incision of

the prostrate (TULIP).

(LLL) Contigen Bard collagen

implant.

(MMM) Dorsal column and deep brain

electrical stimulation of treatment of

motor function disorder.

(NNN) Chelation therapy, except

under specific conditions.

(OOO) All organ transplants except

heart, heart-lung, lung, kidney, some

bone marrow, liver, liver-kidney,

corneal, and heart-valve.

(PPP) Implantable infusion pumps,

except for hepatic artery perfusion

chemotherapy for the treatment of

primary liver cancer or metastatic

colorectal liver cancer.

(QQQ) Services related to the

candidiasis hypersensitivity syndrome,

yeast syndrome, or gastrointestinal

candidiasis (i.e., allergenic extracts of

Candida albicans for immunotherapy

and/or provocation/neutralization).

(RRR) Treatment of chronic fatigue

syndrome.

(SSS) Extracorporeal

immunoadsorption using protein A

columns for conditions other than acute

idiopathic thrombocytopenia purpura.

(TTT) Dynamic posturography (both

static and computerized).

(UUU) Laparoscopic myomectomy.

(VVV) Growth factor, including

platelet-derived growth factors, for

treating non-healing wounds. This

includes procuremen, a plateletderived wound-healing formula.

(WWW) High dose chemotherapy

with stem cell rescue (HDC/SCR) for any

of the following malignancies:.

(1) Breast cancer.

(2) Ovarian cancer.

(3) Testicular cancer.

(4) Multiple myeloma.

* * * * *

Dated: May 11, 1995.

L.M. Bynum,

Alternate OSD Federal Register Liaison

Officer, Department of Defense.

[FR Doc. 95–12031 Filed 5–17–95; 8:45 am]

BILLING CODE 5000–04–M
26710 Federal Register / Vol. 60, No. 96 / Thursday, May 18, 1995 / Proposed Rules

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD09–95–004]

Drawbridge Operation Regulations;

Chicago River, IL

AGENCY: Coast Guard, DOT.

ACTION: Notice of establishment of

negotiated rulemaking committee and

first meeting.

SUMMARY: The Coast Guard establishes a

negotiated rulemaking committee to

develop regulations governing the

operation of Chicago owned

drawbridges over the Chicago River in

Chicago, Illinois and the passage of

recreational vessels under those bridges.

The committee is established in

accordance with the Negotiated

Rulemaking Act of 1990 and the Federal

Advisory Committee Act.

DATES: The first meeting of the

negotiated rulemaking committee will

be held on June 5, 1995 between 9:00

A.M. and 5:00 P.M. Additional meetings

will be held on June 14, 1995, June 20,

1995, June 28, 1995 and July 12, 1995,

at the same times and place, unless

otherwise scheduled by the committee.

ADDRESSES: The committee meetings

will be held in room 326, Ralph H.

Metcalfe Federal Building, 77 West

Jackson Street, Chicago, Illinois, 60604.

FOR FURTHER INFORMATION CONTACT:

Carolyn Malone, Ninth District Bridge

Branch, Ninth Coast Guard District,

1240 East Ninth Street, room 2083,

Cleveland, Ohio, (216) 522–3993

between the hours of 8:00 A.M. and 3:00

P.M. Should the dates, times or location

of any subsequent committee meeting

change, recorded information will be

provided at the above telephone number

outside of those hours.

SUPPLEMENTARY INFORMATION: The Coast

Guard published a notice of intent

(notice) to form a negotiated rulemaking

committee on April 10, 1995 (60 FR

18061). The notice discussed the Coast

Guard’s intention to proceed in

accordance with the Negotiated

Rulemaking Act of 1990 (Pub. L. 101–

648) and establish the Chicago

Drawbridge Negotiated Rulemaking

Committee (committee) to develop

regulations that provide a permanent

and acceptable resolution to the issues

involved in drawbridge openings for

recreational vessels on the Chicago

River. Regulations governing the

operation of the drawbridges are located

at 33 CFR 117.391 and are issued under

the authority of 33 U.S.C. 499. The

notice also identified interests that

would be affected by amendments to the

current regulations. The Coast Guard

solicited comments on the issues raised

in the notice and nominations for

membership on the committee. The

closing date for comments and

nominations was May 8, 1995.

No comments were received on the

issues to be considered by the

committee. Several nominations for

membership were received. Separate

discussions were held by the neutral

facilitator engaged by the Coast Guard

with each of the interests identified in

the notice and with others identified

during the comment period. As a result,

the Coast Guard is establishing the

committee and beginning the

negotiation process. As required by the

Federal Advisory Committee Act (5

U.S.C. App.) (FACA), the committee

charter has been approved by the

Secretary of Transportation and

submitted to the General Services

Administration. The following interests

are represented on the committee: the

City of Chicago, boatyard owners,

boaters, commercial interests in

Chicago, and the Coast Guard.

The first meeting of the committee

will be held in Chicago on June 5, 1995

at the time and location indicated at the

beginning of this notice. The purpose of

the first meeting is to: (1) Discuss the

charter, goals, and mission of the

committee; (2) present the issues to be

considered by the committee; and (3)

approve the organizational protocols by

which the committee will operate. At

the first session, there will be discussion

of the negotiation and rulemaking

process and an explanation of the

statutory basis for the Coast Guard’s

drawbridge regulations.

The schedule of additional meetings

provided earlier in this notice will be

considered by the committee at its first

meeting. In order for new regulations to

be effective for the Fall 1995 close of the

boating season, committee meetings

must be concluded by 12 July 1995.

Therefore, this schedule may be

changed and additional meetings may

be held on short notice. Announcements

of these meetings will be published in

the Federal Register if time for

meaningful advance notice is available.

Information on all meetings of the

committee will be available by calling

(216) 522–3993 or from the contact

person indicated at the beginning of this

notice.

Attendance at committee meetings is

open to the public, subject to space

availability. Persons wishing to present

oral statements at a meeting should

notify the contact person no later than

the day before the meeting. Any member

of the public may submit written

statements to the committee at any time,

also through the contact person.

Dated: May 11, 1995.

Paul J. Pluta,

Captain, United States Coast Guard,

Commander, Ninth Coast Guard District,

Acting.

[FR Doc. 95–12284 Filed 5–17–95; 8:45 am]

BILLING CODE 4910–14–M

ENVIRONMENTAL PROTECTION

AGENCY

40 CFR Part 51

[FRL–5208–2]

Inspection and Maintenance Flexibility

Amendments

AGENCY: Environmental Protection

Agency.

ACTION: Proposed rule; extension of

public comment period.

SUMMARY: This action extends the

comment period to the proposed rule

published on April 28, 1995 (60 FR

20934). EPA is extending the comment

period to June 1, 1995.

DATES: Written comments on the

proposed rule must be received no later

than June 1, 1995. A public hearing is

scheduled for May 17, 1995 and will be

held at Weber’s Inn at 3050 Jackson

Road, Ann Arbor, Michigan 48103, from

9 a.m. through 5 p.m.

ADDRESSES: Interested parties may

submit written comments (in duplicate

if possible) to Public Docket No. A–95–

08. It is requested that a duplicate copy

be submitted to Eugene J. Tierney at the

Office of Mobile Sources, National

Vehicle and Fuel Emissions Laboratory,

2565 Plymouth Road, Ann Arbor,

Michigan, 48105. The docket is located

at the Air Docket, Room M–1500 (6102),

Waterside Mall SW., Washington, DC

20460. The docket may be inspected

between 8:30 a.m. and 12 noon and

between 1:30 p.m. until 3:30 p.m. on

weekdays. A reasonable fee may be

charged for copying docket material.

FOR FURTHER INFORMATION CONTACT:

Eugene J. Tierney, Telephone (313) 668–

4456.

SUPPLEMENTARY INFORMATION:

Background

EPA announced its intent to amend

the I/M Program Requirements in

December 1994 and held stakeholders’

meetings on January 24, 1995 and

January 31, 1995. The proposal creates

a second, less stringent enhanced I/M

performance standard that could be